 Aimmune Therapeutics NASDAQ:AIMT was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research note issued on Monday, Zacks.com reports. The firm currently has a 18.00 price target on the biotechnology companys stock. Zacks Investment Researchs price objective points to a potential upside of 11.73 from the stocks current ... 